City of Hope is one of the world’s most respected institutions for cancer research and biomedical innovation, with a 110-year legacy of scientific discovery that continues to impact millions of people each year. Widely referred to as “the birthplace of biotech,” City of Hope research has led to breakthrough treatments for cancer, diabetes, HIV, sickle cell disease and other serious illnesses. Its scientists helped unlock the healing potential of monoclonal antibodies, invented synthetic human insulin, and contributed to the development of game-changing “smart” cancer drugs such as Herceptin, Rituxan, Erbitux and Avastin – therapies that now benefit more than 100 million people annually. Today, City of Hope is at the forefront of translational research, working to speed cures from lab to life. With more than 1,000 researchers, many of them internationally recognized leaders in their fields, City of Hope continues to push the boundaries of what’s possible in precision medicine, immunotherapy, genomics and cellular therapies. It is among the few institutions in the country to house two on-campus Good Manufacturing Practices (GMP) facilities, giving its scientists the rare ability to move novel therapeutic discoveries quickly and cost-effectively into clinical trials. The organization leads more than 700 active clinical trials and is a global leader in CAR T cell therapy, having treated more than 1,600 patients to date. Its scientists have also pioneered outpatient delivery of CAR T treatments – making advanced therapies more accessible and more affordable. In genomics, City of Hope is pursuing the ambitious goal of sequencing every cancer patient’s tumor to tailor the most precise and effective treatment plan possible.
